Search

everythinglearnresearchcommunity

for

Search:↓

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

Exposure to too much androgen before birth might cause polycystic ovary syndrome later in life.

5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.

The document concludes that accurate diagnosis and personalized treatment are important for skin problems in women with PCOS.

Lifestyle changes are the main treatment for PCOS, which is a complex condition requiring early management to reduce its health impacts.

Women with nonclassic congenital adrenal hyperplasia experience more sexual dysfunction and distress.

Finasteride can have lasting negative effects on brain function and behavior by disrupting neurosteroid production.

AKR1C3 could be a treatment target for metabolic issues in PCOS.

New treatments for male hypogonadism are effective and should be personalized.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

Ovarian Hyperthecosis caused hypersexuality in an older woman and was successfully treated with surgery.

A boy with a new NR5A1 gene mutation has a sex development disorder without affecting his adrenal glands.

The removed ovarian tumor was a rare type of blood vessel tumor that improved the patient's symptoms and hormone levels after surgery.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

The hypothesis suggests that PCOS may start early in life due to genetic and environmental factors, influencing future reproductive and metabolic problems.

Oestrogens are key for bone growth during puberty in both boys and girls.

The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Stress from being transgender is linked to higher blood pressure at night and more inflammation, which may affect heart health.

The document concludes that managing non-classical congenital adrenal hyperplasia in females requires personalized treatment, genetic counseling, and a team of specialists.

Testosterone affects brain functions and contributes to sex differences, influencing conditions like autism.

CAH is a genetic disorder affecting cortisol production and causing hormonal imbalances, with treatment and diagnosis varying by form and symptoms.

Estrogens are key for bone growth spurts in both boys and girls and affect growth into adulthood.

The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.

The safety and effectiveness of gender-affirming treatments for children are uncertain, with potential long-term risks like infertility.

A thorough initial check-up is essential before sperm banking to ensure the best chance of preserving good quality sperm.

Genetic mutations can affect female sexual development, requiring personalized medical care.

The document concludes that transsexual individuals often experience improved quality of life after transitioning, despite higher risks of psychiatric issues and mortality.

Genetic defects in testosterone production can cause hormonal and developmental disorders, and more research is needed to understand androgen regulation and develop safer treatments.

Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.